Welcome!

News Feed Item

PharmaPoint: Crohn's Disease - India Drug Forecast and Market Analysis to 2022

NEW YORK, April 9, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

 

PharmaPoint: Crohn's Disease - India Drug Forecast and Market Analysis to 2022

http://www.reportlinker.com/p02063644/PharmaPoint-Crohn's-Disease---India-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

 

PharmaPoint: Crohn's Disease - India Drug Forecast and Market Analysis to 2022

 

Summary

 

The Crohn's disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds will challenge the current biologics in an attempt to dislodge the stronghold of the TNF inhibitors, as they aim to tap into the lucrative portion of the CD therapeutics market. If their promising safety and efficacy profiles translate to clinical practice once they enter the market, their launch will be to the detriment of the existing market leaders, Remicade (infliximab) and Humira (adalimumab).The loss of patent protection of the anti-TNF marketed brands will allow for the emergence of biosimilars, such as Hospira's Inflectra (infliximab) a Remicade biosimilar. Focusing on country dynamics, Canada and the emerging markets of China and India will also play a key role in driving growth in the long term, with each market forecast to post positive Compound Annual Growth Rates (CAGRs) from 2012 to 2022, primarily due to the anticipated strong uptake of Remicade over the forecast period.

 

For the treatment of CD, Indian physicians rely heavily on non-pharmacological methods, such as dietary recommendations, and for pharmacologic therapy, they use generic products within the corticosteroids and 5-ASAs. GlobalData's physician survey showed that these drugs are the mainstay of treatment for mild to moderate CD in India, as well as at earlier lines of therapy for severe disease. While Indian physicians commonly prescribe domestic generics and biosimilars, our primary research revealed that biosimilars were not readily available to those with CD.

 

Scope

 

- Overview of Crohn's disease including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

- Detailed information on the key drugs in India including product description, safety and efficacy profiles as well as a SWOT analysis.

- Sales forecast for the top drugs in India from 2012-2022.

- Analysis of the impact of key events as well the drivers and restraints affecting the India Crohn's disease market.

 

Reasons to buy

 

- Understand and capitalize by identifying products that are most likely to ensure a robust return.

- Stay ahead of the competition by understanding the changing competitive landscape for Crohn's disease.

- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.

- Make more informed business decisions from insightful and in-depth analysis of drug performance.

- Obtain sales forecast for drugs from 2012-2022 in India.

1 Table of Contents

2 Introduction 9

2.1 Catalyst 9

2.2 Related Reports 10

2.3 Upcoming Related Reports 11

3 Disease Overview 12

3.1 Etiology and Pathophysiology 12

3.1.1 Etiology 12

3.1.2 Pathophysiology 12

3.2 Symptoms 16

3.3 Prognosis 17

3.4 Quality of Life 18

4 Disease Management 19

4.1 Treatment Overview 20

4.2 India 25

4.2.1 Diagnosis 25

4.2.2 Clinical Practice 25

5 Competitive Assessment 27

5.1 Overview 27

5.2 Strategic Competitor Assessment 28

5.3 Product Profiles - Major Brands 29

5.3.1 Remicade (infliximab) 29

5.3.2 Other Marketed Products 35

6 Opportunity and Unmet Need 36

6.1 Overview 36

6.2 Physicians Desire Biomarkers That Will Allow a Personalized Treatment Approach 37

6.3 More Therapies for Anti-TNF-Refractory Patients 38

6.4 Unmet Needs Gap Analysis 39

6.5 Targeted Therapies 40

6.6 Predictive Tools for Early Diagnosis and Treatment 41

7 Pipeline Assessment 42

7.1 Overview 42

7.2 Promising Drugs in Clinical Development 42

7.3 Other Late-Stage Pipeline Products 44

7.3.1 Cx601 44

7.3.2 RHB-104 (clarithromycin + clofazimine + rifabutin) 46

8 Market Outlook 51

8.1 Global Markets 51

8.1.1 Drivers and Barriers - Global Issues 51

9 India 56

9.1 Forecast 56

9.2 Key Events 58

9.3 Drivers and Barriers 59

9.3.1 Driver: Continued investment in the national healthcare system and services 59

9.3.2 Driver: Sizeable CD patient population that will increase over the coming decade 59

9.3.3 Barrier: Loose intellectual property policies present a major challenge for developers with novel drugs 60

9.3.4 Barrier: Limited access to and the high price point of CD therapies, coupled with many Indians' belief in traditional medicine, negatively impacts branded drug sales 60

9.3.5 Barrier: Downward pricing pressure limits drug sales growth 61

10 Appendix 62

10.1 Bibliography 62

10.2 Abbreviations 67

10.3 Methodology 71

10.4 Forecasting Methodology 71

10.4.1 Diagnosed CD Patients 71

10.4.2 Percent Drug-Treated Patients 72

10.4.3 Drugs Included in Each Therapeutic Class 72

10.4.4 General Pricing Assumptions 72

10.4.5 Individual Drug Assumptions 74

10.4.6 Generic Erosion 74

10.5 Physicians and Specialists Included in This Study 75

10.6 Primary Research - Prescriber Survey 76

10.7 About the Authors 77

10.7.1 Author/Reviewer 77

10.7.2 Global Head of Healthcare 77

10.8 About GlobalData 78

10.9 Disclaimer 78

 

1.1 List of Tables

 

Table 1: Symptoms of CD 17

Table 2: Treatment Guidelines for CD 21

Table 3: Most Commonly Prescribed Drugs for CD in the Global Markets by Disease Severity, 2013 23

Table 4: Leading Branded Drugs Used to Treat CD 29

Table 5: Product Profile - Remicade 31

Table 6: Remicade SWOT Analysis, 2013 34

Table 7: Summary of the Minor Therapeutic Classes in CD, 2013 35

Table 8: Overall Unmet Needs in CD - Current Level of Attainment 37

Table 9: Clinical Unmet Needs in CD - Gap Analysis, 2013 40

Table 10: Promising Drugs in Clinical Development for CD - Pipeline Phase, 2013 42

Table 11: Comparison of Therapeutic Classes in Development for CD, 2013 43

Table 12: Product Profile - Cx601 45

Table 13: Cx601 SWOT Analysis, 2013 46

Table 14: Product Profile - RHB-104 48

Table 15: RHB-104 SWOT Analysis, 2013 50

Table 16: Global CD Market - Drivers and Barriers, 2012-2022 51

Table 17: Sales Forecasts ($) for CD in India, 2012-2022 57

Table 18: Key Events Impacting Sales for CD in India, 2012-2022 58

Table 19: CD Market in India - Drivers and Barriers, 2012-2022 59

Table 20: Physicians Surveyed, By Country 76

 

1.2 List of Figures

 

Figure 1: Mucosa of the Bowel in a Healthy Individual (Left) and a Patient With CD (Right) 13

Figure 2: Potential Biologic Drug Targets for CD 16

Figure 3: Patient Care Path for CD 22

Figure 4: Competitive Assessment of Late-Stage Pipeline Agents in CD, 2012-2022 43

Figure 5: Sales for CD in India by Drug Class, 2012-2022 58

 

 

To order this report: PharmaPoint: Crohn's Disease - India Drug Forecast and Market Analysis to 2022

http://www.reportlinker.com/p02063644/PharmaPoint-Crohn's-Disease---India-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

Contact Clare: [email protected]
US:(339) 368 6001
Intl:+1 339 368 6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
As hybrid cloud becomes the de-facto standard mode of operation for most enterprises, new challenges arise on how to efficiently and economically share data across environments. In his session at 21st Cloud Expo, Dr. Allon Cohen, VP of Product at Elastifile, will explore new techniques and best practices that help enterprise IT benefit from the advantages of hybrid cloud environments by enabling data availability for both legacy enterprise and cloud-native mission critical applications. By rev...
When it comes to cloud computing, the ability to turn massive amounts of compute cores on and off on demand sounds attractive to IT staff, who need to manage peaks and valleys in user activity. With cloud bursting, the majority of the data can stay on premises while tapping into compute from public cloud providers, reducing risk and minimizing need to move large files. In his session at 18th Cloud Expo, Scott Jeschonek, Director of Product Management at Avere Systems, discussed the IT and busine...
Organizations do not need a Big Data strategy; they need a business strategy that incorporates Big Data. Most organizations lack a road map for using Big Data to optimize key business processes, deliver a differentiated customer experience, or uncover new business opportunities. They do not understand what’s possible with respect to integrating Big Data into the business model.
Companies are harnessing data in ways we once associated with science fiction. Analysts have access to a plethora of visualization and reporting tools, but considering the vast amount of data businesses collect and limitations of CPUs, end users are forced to design their structures and systems with limitations. Until now. As the cloud toolkit to analyze data has evolved, GPUs have stepped in to massively parallel SQL, visualization and machine learning.
Recently, REAN Cloud built a digital concierge for a North Carolina hospital that had observed that most patient call button questions were repetitive. In addition, the paper-based process used to measure patient health metrics was laborious, not in real-time and sometimes error-prone. In their session at 21st Cloud Expo, Sean Finnerty, Executive Director, Practice Lead, Health Care & Life Science at REAN Cloud, and Dr. S.P.T. Krishnan, Principal Architect at REAN Cloud, will discuss how they b...
Enterprises have taken advantage of IoT to achieve important revenue and cost advantages. What is less apparent is how incumbent enterprises operating at scale have, following success with IoT, built analytic, operations management and software development capabilities – ranging from autonomous vehicles to manageable robotics installations. They have embraced these capabilities as if they were Silicon Valley startups. As a result, many firms employ new business models that place enormous impor...
The next XaaS is CICDaaS. Why? Because CICD saves developers a huge amount of time. CD is an especially great option for projects that require multiple and frequent contributions to be integrated. But… securing CICD best practices is an emerging, essential, yet little understood practice for DevOps teams and their Cloud Service Providers. The only way to get CICD to work in a highly secure environment takes collaboration, patience and persistence. Building CICD in the cloud requires rigorous a...
SYS-CON Events announced today that Dasher Technologies will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Dasher Technologies, Inc. ® is a premier IT solution provider that delivers expert technical resources along with trusted account executives to architect and deliver complete IT solutions and services to help our clients execute their goals, plans and objectives. Since 1999, we'v...
SYS-CON Events announced today that MIRAI Inc. will exhibit at the Japan External Trade Organization (JETRO) Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. MIRAI Inc. are IT consultants from the public sector whose mission is to solve social issues by technology and innovation and to create a meaningful future for people.
Data scientists must access high-performance computing resources across a wide-area network. To achieve cloud-based HPC visualization, researchers must transfer datasets and visualization results efficiently. HPC clusters now compute GPU-accelerated visualization in the cloud cluster. To efficiently display results remotely, a high-performance, low-latency protocol transfers the display from the cluster to a remote desktop. Further, tools to easily mount remote datasets and efficiently transfer...
In his session at 21st Cloud Expo, Raju Shreewastava, founder of Big Data Trunk, will provide a fun and simple way to introduce Machine Leaning to anyone and everyone. Together we will solve a machine learning problem and find an easy way to be able to do machine learning without even coding. Raju Shreewastava is the founder of Big Data Trunk (www.BigDataTrunk.com), a Big Data Training and consulting firm with offices in the United States. He previously led the data warehouse/business intellige...
SYS-CON Events announced today that TidalScale, a leading provider of systems and services, will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. TidalScale has been involved in shaping the computing landscape. They've designed, developed and deployed some of the most important and successful systems and services in the history of the computing industry - internet, Ethernet, operating s...
SYS-CON Events announced today that TidalScale will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. TidalScale is the leading provider of Software-Defined Servers that bring flexibility to modern data centers by right-sizing servers on the fly to fit any data set or workload. TidalScale’s award-winning inverse hypervisor technology combines multiple commodity servers (including their ass...
Gemini is Yahoo’s native and search advertising platform. To ensure the quality of a complex distributed system that spans multiple products and components and across various desktop websites and mobile app and web experiences – both Yahoo owned and operated and third-party syndication (supply), with complex interaction with more than a billion users and numerous advertisers globally (demand) – it becomes imperative to automate a set of end-to-end tests 24x7 to detect bugs and regression. In th...
Amazon is pursuing new markets and disrupting industries at an incredible pace. Almost every industry seems to be in its crosshairs. Companies and industries that once thought they were safe are now worried about being “Amazoned.”. The new watch word should be “Be afraid. Be very afraid.” In his session 21st Cloud Expo, Chris Kocher, a co-founder of Grey Heron, will address questions such as: What new areas is Amazon disrupting? How are they doing this? Where are they likely to go? What are th...